Only moderately admired on release, it stands up rather well as a summation of an ageing artist's vision, gaining in wistful power as its strange, rapturous vignettes flow into each other.
We will see how quickly our vision gains momentum.
Still, the authors of the study said that giving the drugs as needed, which resulted in average vision gains around six letters, could be an acceptable alternative.
As these agents are primarily used on a pro re nata (PRN) dosing schedule (because neither patients nor physicians want monthly injections), the factors involved in making the treatment and retreatment decisions are very important in any attempt to maximize vision gain.
The vision gains reported with monthly intravitreal ranibizumab in the MARINA and ANCHOR trials led to an immediate paradigm shift in the treatment of neovascular AMD with retina physicians universally switching to the pan-VEGF blocking agents ranibizumab and bevacizumab, and patients expecting visual improvement.
Which is why it is so critical that Focus on Vision gains well-deserved support for their heroic efforts.
Most studies with limited or no vision gain explain their results with the long-standing disease.
Treatment with threshold or subthreshold grid laser also resulted in minimal vision gain.
However, at 24 months both combination therapy (1.290 lines) and threshold grid laser alone led to a similar vision gain.
Efforts to stretch the ranibizumab dosing interval to 3 months (PIER) resulted in forfeiting previous vision gains.
At 12 months from laser, the vision gain was 7.8 letters from baseline (p<0.01), with no significant change compared with the gain at 12 months from baseline (p=0.108).
